Large insurers reducing their involvement in the Affordable Care Act health insurance exchanges doesn't necessarily indicate failure, but success is not guaranteed, said Michael E. Chernew, PhD.
Large insurers reducing their involvement in the Affordable Care Act health insurance exchanges doesn't necessarily indicate failure, but success is not guaranteed, said Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and director of the Healthcare Markets and Regulation Lab at Harvard Medical School, as well as co-editor-in-chief of The American Journal of Managed Care.
Transcript (slightly modified)
What is your opinion on the sustainability of the Affordable Care Act with large insurers pulling back on their involvement in the exchanges?
I think it's too early to tell how well the exchanges will stabilize. It's certainly concerning when insurers pull out. But other insurers are expanding. There are some markets that probably have too few carriers to maintain real competition, many of those are rural markets. But there are others—many urban markets you still have vigorous competition on the exchanges.
So insurers, largely, would not be expected to participate on the exchanges that they were losing money, and many of the larger insurers were. So they've opted not to participate. It remains to be seen in the future if they get back in, if the market stabilizes, if there are enough competitors. Right now, we're far from failure, but success isn't guaranteed.
What is the importance of new insurers entering the ACA exchanges as insurers like Aetna and UnitedHealth Group reduce their involvement?
It varies by market, in general. You don't want to have too many carriers, because it makes choice very hard. On the other hand, there are some markets that have too few. So there are selected places—my understanding is that North Carolina and other places—where it would be important to have more competitive insurers potentially as some of the insurers pull out. Others, it's less important.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More